These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 27757851)
1. Demethoxycurcumin was superior to temozolomide in the inhibition of the growth of glioblastoma stem cells in vivo. Leng L; Zhong X; Sun G; Qiu W; Shi L Tumour Biol; 2016 Oct; ():. PubMed ID: 27757851 [TBL] [Abstract][Full Text] [Related]
2. Demethoxycurcumin was prior to temozolomide on inhibiting proliferation and induced apoptosis of glioblastoma stem cells. Shi L; Fei X; Wang Z Tumour Biol; 2015 Sep; 36(9):7107-19. PubMed ID: 25877753 [TBL] [Abstract][Full Text] [Related]
3. Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro. Shi L; Sun G Neuromolecular Med; 2015 Dec; 17(4):431-42. PubMed ID: 26458914 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA 145 enhances chemosensitivity of glioblastoma stem cells to demethoxycurcumin. Qian C; Wang B; Zou Y; Zhang Y; Hu X; Sun W; Xiao H; Liu H; Shi L Cancer Manag Res; 2019; 11():6829-6840. PubMed ID: 31440081 [No Abstract] [Full Text] [Related]
5. DMC is not better than TMZ on intracranial anti-glioma effects. Shi L; Sun G J Cell Biochem; 2018 Jul; 119(7):6057-6064. PubMed ID: 29575236 [TBL] [Abstract][Full Text] [Related]
6. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059 [TBL] [Abstract][Full Text] [Related]
7. Demethoxycurcumin analogue DMC-BH inhibits orthotopic growth of glioma stem cells by targeting JNK/ERK signaling. Shi L; Sun G; Zhu H Aging (Albany NY); 2020 Jul; 12(14):14718-14735. PubMed ID: 32710727 [TBL] [Abstract][Full Text] [Related]
8. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Noh H; Zhao Q; Yan J; Kong LY; Gabrusiewicz K; Hong S; Xia X; Heimberger AB; Li S Cancer Lett; 2018 Oct; 433():176-185. PubMed ID: 29991446 [TBL] [Abstract][Full Text] [Related]
9. Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma. Zheng Y; Liu L; Wang Y; Xiao S; Mai R; Zhu Z; Cao Y Cell Biosci; 2021 Mar; 11(1):63. PubMed ID: 33789726 [TBL] [Abstract][Full Text] [Related]
10. Role of autophagy in regulation of glioma stem cells population during therapeutic stress. Abbas S; Singh SK; Saxena AK; Tiwari S; Sharma LK; Tiwari M J Stem Cells Regen Med; 2020; 16(2):80-89. PubMed ID: 33414584 [TBL] [Abstract][Full Text] [Related]
11. Nitric Oxide Prevents Glioblastoma Stem Cells' Expansion and Induces Temozolomide Sensitization. Salvatori L; Malatesta S; Illi B; Somma MP; Fionda C; Stabile H; Fontanella RA; Gaetano C Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511047 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 inhibitor sensitizes human glioblastoma U251 stem cells to chemotherapeutic drug temozolomide. Zhang S; Wan Y; Pan T; Gu X; Qian C; Sun G; Sun L; Xiang Y; Wang Z; Shi L J Mol Neurosci; 2012 Jun; 47(2):346-56. PubMed ID: 22528454 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide. Tentori L; Ricci-Vitiani L; Muzi A; Ciccarone F; Pelacchi F; Calabrese R; Runci D; Pallini R; Caiafa P; Graziani G BMC Cancer; 2014 Mar; 14():151. PubMed ID: 24593254 [TBL] [Abstract][Full Text] [Related]
14. PI3K inhibitor combined with miR-125b inhibitor sensitize TMZ-induced anti-glioma stem cancer effects through inactivation of Wnt/β-catenin signaling pathway. Shi L; Fei X; Wang Z; You Y In Vitro Cell Dev Biol Anim; 2015 Nov; 51(10):1047-55. PubMed ID: 26170223 [TBL] [Abstract][Full Text] [Related]
15. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway. Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060 [TBL] [Abstract][Full Text] [Related]
16. Identification of GSK3β inhibitor kenpaullone as a temozolomide enhancer against glioblastoma. Kitabayashi T; Dong Y; Furuta T; Sabit H; Jiapaer S; Zhang J; Zhang G; Hayashi Y; Kobayashi M; Domoto T; Minamoto T; Hirao A; Nakada M Sci Rep; 2019 Jul; 9(1):10049. PubMed ID: 31296906 [TBL] [Abstract][Full Text] [Related]
17. Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma. Gao XY; Zang J; Zheng MH; Zhang YF; Yue KY; Cao XL; Cao Y; Li XX; Han H; Jiang XF; Liang L Front Cell Dev Biol; 2021; 9():620883. PubMed ID: 33614649 [TBL] [Abstract][Full Text] [Related]
18. ABCG2 downregulation in glioma stem cells enhances the therapeutic efficacy of demethoxycurcumin. Chen L; Shi L; Wang W; Zhou Y Oncotarget; 2017 Jun; 8(26):43237-43247. PubMed ID: 28591733 [TBL] [Abstract][Full Text] [Related]
19. Tubeimoside-I sensitizes temozolomide-resistant glioblastoma cells to chemotherapy by reducing MGMT expression and suppressing EGFR induced PI3K/Akt/mTOR/NF-κB-mediated signaling pathway. Tang Q; Cao H; Tong N; Liu Y; Wang W; Zou Y; Xu L; Zeng Z; Xu W; Yin Z; Ma W; Wang Q Phytomedicine; 2022 May; 99():154016. PubMed ID: 35278900 [TBL] [Abstract][Full Text] [Related]
20. Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein. Zhitao J; Long L; Jia L; Yunchao B; Anhua W Tumour Biol; 2015 Dec; 36(12):9621-30. PubMed ID: 26142735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]